Listed

LENZ Therapeutics, Inc.: Form 10-K for the period ended Dec 31, 2022

Filed with the SEC on Mar 20, 2023 and accepted by EDGAR at Mar 20, 2023, 20:11 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development12 months2022-01-01 to 2022-12-31$72.8mus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2022-01-01 to 2022-12-31−$105.6mus-gaap:OperatingIncomeLoss
Income tax12 months2022-01-01 to 2022-12-31$0us-gaap:IncomeTaxExpenseBenefit
Net income12 months2022-01-01 to 2022-12-31−$101.1mus-gaap:NetIncomeLoss
Diluted EPS12 months2022-01-01 to 2022-12-31−$1.84us-gaap:EarningsPerShareDiluted
Basic EPS12 months2022-01-01 to 2022-12-31−$1.84us-gaap:EarningsPerShareBasic
Diluted shares (weighted)12 months2022-01-01 to 2022-12-3154,873,675 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow12 months2022-01-01 to 2022-12-31−$88.0mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2022-01-01 to 2022-12-31$6.6mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2022-12-31$47.7mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2022-12-31$275.4mus-gaap:AssetsCurrent
Total assetsAt period end2022-12-31$321.9mus-gaap:Assets
Current liabilitiesAt period end2022-12-31$13.0mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2022-12-31$25.6mus-gaap:Liabilities
Shareholders' equityAt period end2022-12-31$296.3mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000950170-23-008764. Last ingested by Listed: Oct 24, 2026, 15:06 ET. Listed shows no prices and gives no investment advice.